Results 101 to 110 of about 4,251 (181)

Acalabrutinib

Reactions Weekly, 2022
  +4 more sources

Acalabrutinib Maleate Tablets: The Physiologically Based Biopharmaceutics Model behind the Drug Product Dissolution Specification

Acalabrutinib maleate tablets correspond to an improved formulation compared to acalabrutinib capsules as they can be dosed with and without acid reducing agents and therefore benefit more cancer patients.
James Mann (4385431), Vivien McAlpine (14704241), Xavier Pepin (14704238), Andrea Moir (14704244)   +3 more
core   +1 more source

Clinical Safety Profile of Bruton's Tyrosine Kinase (BTK) Inhibitors in Chronic Lymphocytic Leukaemia: A Real-World Ambispective Study From India. [PDF]

Cureus
Pradhan A, Panchal HP.
europepmc   +1 more source

Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia. [PDF]

Blood Adv
Furman RR, Wierda WG, Patten PEM, Chaves JM, Brown JR, Munir T, Martin P, Awan FT, Stephens DM, Ghia P, Barrientos JC, Patel K, Woyach JA, de Borja M, Wang MH, Jain N, O'Brien SM, Byrd JC.   +17 more
europepmc   +1 more source

First-Line Treatment of Chronic Lymphocytic Leukemia in Italy: Real-World Evidence on Utilization, Outcomes, and Healthcare Costs. [PDF]

Clinicoecon Outcomes Res
Perrone V, Innao V, Mazzoni S, Cappuccilli M, Andretta M, Bartolini F, Chinellato A, Dell'Orco S, Ferrante F, Lombardi R, Pagliaro R, Ubertazzo L, Valpondi P, Degli Esposti L.   +13 more
europepmc   +1 more source

An indirect comparison of zanubrutinib vs acalabrutinib plus venetoclax in patients with treatment-naive CLL. [PDF]

Blood Adv
Shadman M, Tam CS, Brander DM, Lefebure M, Yang K, Xu S, Tian T, Kuptsova-Clarkson N, Williams R, Hirata J, Munir T.   +10 more
europepmc   +1 more source

Inhibition of acalabrutinib metabolism by finerenone and its molecular docking studies. [PDF]

Cell Biol Toxicol
Wang P, Fu H, Wu J, Li R, Cao L, Xu RA, Lin W.   +6 more
europepmc   +1 more source

Economic Evaluation of Bruton's Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukaemia in South Africa. [PDF]

Appl Health Econ Health Policy
Woudberg R, Sinanovic E.
europepmc   +1 more source

Chronic Lymphocytic Leukemia: Molecular Pathologies and Therapeutic Strategies. [PDF]

Int J Mol Sci
Meza K, Barrientos Risso C, Shah A, Romagnoli C, Sandoval J, Brauchle Y, Lyubimova A, Santos L, Goya Balaguer E, Barrientos J.   +9 more
europepmc   +1 more source

Impact of Market Access Delays on Time to Patient Access: Multi-Country Comparative Analysis Assessing the First Commercial Launch Indications for Five Oncology Medicines Across Europe and Canada. [PDF]

J Mark Access Health Policy
Crean B, Parry D, Horsfield A, Ryan J, Oraiopoulos N.   +4 more
europepmc   +1 more source